No connection

Search Results

LQDA vs OGN

LQDA
Liquidia Corporation
NEUTRAL
Price
$38.85
Market Cap
$3.42B
Sector
Healthcare
AI Confidence
75%
OGN
Organon & Co.
BEARISH
Price
$13.25
Market Cap
$3.48B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
LQDA
--
OGN
14.1
Forward P/E
LQDA
7.42
OGN
3.59
P/B Ratio
LQDA
75.73
OGN
4.59
P/S Ratio
LQDA
21.62
OGN
0.56
EV/EBITDA
LQDA
-68.03
OGN
7.07

Profitability

Gross Margin
LQDA
91.64%
OGN
54.34%
Operating Margin
LQDA
21.5%
OGN
16.19%
Profit Margin
LQDA
-43.54%
OGN
3.01%
ROE
LQDA
-111.05%
OGN
30.56%
ROA
LQDA
-11.5%
OGN
6.22%

Growth

Revenue Growth
LQDA
3054.6%
OGN
-5.3%
Earnings Growth
LQDA
--
OGN
--

Financial Health

Debt/Equity
LQDA
4.42
OGN
11.7
Current Ratio
LQDA
2.01
OGN
1.82
Quick Ratio
LQDA
1.8
OGN
0.84

Dividends

Dividend Yield
LQDA
--
OGN
0.6%
Payout Ratio
LQDA
0.0%
OGN
47.22%

AI Verdict

LQDA NEUTRAL

Liquidia Corporation presents a high-risk, high-reward profile characterized by a critical Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company has achieved explosive revenue growth (3054.60% YoY) and maintains a strong gross margin of 91.64%, its balance sheet is distressed with a Debt/Equity ratio of 4.42 and an ROE of -111.05%. The market is pricing in significant future success, as evidenced by a Price/Book ratio of 75.73, though insider selling and a bearish technical trend suggest a potential near-term peak. The disconnect between analyst optimism (Buy rating) and deterministic health scores necessitates a neutral stance.

Strengths
Explosive revenue growth of 3054.60% YoY
Exceptional gross margins (91.64%) typical of high-value specialty drugs
Positive operating margin (21.50%) suggesting core business viability
Risks
Critical fundamental health (Piotroski F-Score 1/9)
Extreme valuation premiums (Price/Book 75.73, Price/Sales 21.62)
High leverage with a Debt/Equity ratio of 4.42
OGN BEARISH

OGN presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) and a critical Debt/Equity ratio of 11.70. While the stock has experienced a massive speculative rally over the last 60 days, the current price of $13.25 is significantly decoupled from its Graham Number ($7.82) and Intrinsic Value ($6.58). Fundamental deterioration is evident in the -5.30% revenue growth and -30.4% YoY EPS growth, suggesting the recent price surge is not supported by operational performance.

Strengths
Strong Gross Margin (54.34%)
High ROE (30.56%), though likely inflated by high leverage
Healthy Current Ratio (1.82) providing short-term liquidity
Risks
Extreme leverage with a Debt/Equity ratio of 11.70
Negative revenue growth (-5.30% YoY)
Significant overvaluation relative to Graham and Intrinsic values

Compare Another Pair

LQDA vs OGN: Head-to-Head Comparison

This page compares Liquidia Corporation (LQDA) and Organon & Co. (OGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile